目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T12441 | Monoamine Oxidase | ||
Phenelzine sulfate 是一种非选择性的、不可逆的单胺氧化酶抑制剂 (MAOI),可用作抗抑郁药和抗焦虑药。 | |||
T1578 | MAO Monoamine Oxidase | ||
Pargyline hydrochloride (Pargylamine hydrochloride) 是不可逆的单胺氧化酶抑制剂,可作用于 MAO-A (Ki=13 μM) 和 MAO-B (Ki=0.5 μM) ,具有降压和抗癌作用。 | |||
T39986 | Lipoxygenase | ||
LOX-IN-3 dihydrochloride 是口服有效的赖氨酰氧化酶抑制剂,在纤维化,癌症和/或血管生成方面有研究价值。 | |||
T18918 | MAO Monoamine Oxidase | ||
Azure B (Azure B chloride) 是一种 Methylene blue 的主要代谢物,是一种阳离子染料,用于 Azure 曙红染色剂以进行血液涂片染色。它是高选择性和可逆的抑制单胺氧化酶(MAO)-A 的抑制剂,对重组人的 MAO-A 和 MAO-B 的IC50分别为 11 和 968 nM。它具有显著的抗抑郁作用。 | |||
T0719 | Others Dopamine Receptor Monoamine Transporter | ||
Tetrabenazine (Ro 1-9569) 是 VMAT 抑制剂,用作抗精神病药和治疗各种运动障碍。 | |||
T5053 | MAO Monoamine Oxidase | ||
Eprobemide (LIS 630) 是一种非竞争性的、可逆的单胺氧化酶 A 抑制剂。 | |||
T0300 | MAO Monoamine Oxidase | ||
Pargyline (Pargylamine) 是不可逆的单胺氧化酶抑制剂,对MAO-A 和MAO-B 的Ki 分别为 13 μM 和 0.5 μM,具有降压和抗癌作用。 | |||
T7942 | Histone Demethylase MAO Monoamine Oxidase | ||
Tranylcypromine hemisulfate (Tranylcypromine Sulfate) 是单胺氧化酶(MAO) 和赖氨酸特异性去甲基化酶 1 (LSD1) 的抑制剂,可用于研究抑郁症和子宫内膜异位症。 | |||
T23070 | Sodium Channel Monoamine Transporter Norepinephrine | ||
Nisoxetine hydrochloride 是一种去甲肾上腺素转运蛋白 (NET) 抑制剂,Kd 值为 0.76 nM。它是抗抑郁药和局部麻药,可以阻断电压门控性钠通道。 | |||
T3885 | Others Monoamine Oxidase | ||
Rosiridin (6'-O-Deacetylrosiridoside C) 能够抑制 MAO A 和 MAO B,有潜在的抑郁症和老年性痴呆作用。它在 10 μM 时对 MAO B 的抑制率为 83.8% (pIC50=5.38)。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPJ-00379 | AOC3 Protein, Human, Recombinant (hFc) | Human | Human Cells | ||
Membrane primary amine oxidase(AOC3), also known as vascular adhesion protein (VAP-1) and HPAO, this protein is a member of the semicarbazide-sensitive amine oxidase (SSAO) family. VAP-1 is a type 1 membrane-bound glycoprotein that has a distal adhesion domain and an enzymatically active amine oxidase site outside of the membrane, VAP-1 has adhesive properties, functional monoamine oxidase activity, and possibly plays a role in glucose handling, leukocyte trafficking, and migration during inflammation. This rise in metabolic products contributes to generating advanced glycation end-products and oxidative stress along with the monoamine detoxification in the organism. It is highly expressed on the endothelium of the lung and trachea, and absent from leukocytes and epithelial cells. Membrane-bound VAP-1 releases an active, soluble form of the protein, which may be conducive to increased inflammation and the progression of many vascular disorders. In particular, elevation of VAP-1 activity and the increased enzymatic-mediated deamination is proposed to play a role in renal and vascular disease, oxidative stress, acute and chronic hyperglycemia, and diabetes complications.
|
|||||
TMPY-00506 | GAPDH Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH or G3PDH) is an enzyme of about 37kDa that is consisdered as a cellular enzyme involved in glycolysis. It catelyzes the sixth step of glycolysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Its role as a mediator for cell death has also been highlighted. A recent report suggests that GAPDH may be genetically associated with late-onset of Alzheimer's disease. Besides, deprenyl, which has originally been used as a monoamine oxidase inhibitor for Parkinson's disease, binds to GAPDH and displays neuroprotective actions.
|
|||||
TMPY-02446 | GAPDH Protein, Human, Recombinant (His) | Human | E. coli | ||
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH or G3PDH) is an enzyme of about 37kDa that is consisdered as a cellular enzyme involved in glycolysis. It catelyzes the sixth step of glycolysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Its role as a mediator for cell death has also been highlighted. A recent report suggests that GAPDH may be genetically associated with late-onset of Alzheimer's disease. Besides, deprenyl, which has originally been used as a monoamine oxidase inhibitor for Parkinson's disease, binds to GAPDH and displays neuroprotective actions.
|
|||||
TMPY-03056 | LSD1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
LSD1 belongs to the flavin monoamine oxidase family. It contains 1 SWIRM domain and is a component of an RCOR/GFI/LSD1/HDAC complex. LSD1 interacts directly with GFI1 and GFI1B. LSD1 specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 through a FAD-dependent oxidative reaction. When forming a complex with an androgen receptor (and possibly other nuclear hormone receptors), LSD1 changes its substrates to H3K9me2. Thus LSD1 is considered to act as a coactivator or a corepressor. It may play a role in the repression of neuronal genes. Alone, LSD1 is unable to demethylate H3 'Lys-4' on nucleosomes and requires the presence of RCOR1/CoREST to achieve such activity.
|